Novel benzo [d ]oxazol-2(3H )-one derivatives were designed and synthesized, and their affinities against σ receptors were evaluated. On the basis of 31 compounds, a three-dimensional pharmacophore model for the σ 1 receptor binding site was developed using the Catalyst 4.9 software package. The best 3D pharmacophore hypothesis, consisting of one positive ionizable, one hydrogen bond acceptor, two hydrophobic aromatic, and one hydrophobic features provided a 3D-QSAR model with a correlation coefficient of 0.89. The best hypothesis was also validated by three independent methods, i.e., the Fisher randomization test included in the CatScramble functionality of Catalyst, the leave-one-out test, and activity prediction of an additional test set. The achieved results will allow researchers to use this 3D pharmacophore model for the design and synthesis of a second generation of high affinity σ 1 ligands, as well as to discover other lead compounds for this class of receptors.
Introduction
The σ binding sites were originally defined and classified as opioid receptor subtypes. 1 Later investigations demonstrated that σ receptors were distinct from opioid and phencyclidine analogues, and since then, at least two distinct σ receptor subtypes, designated σ 1 and σ 2 , 2 have been pharmacologically characterized. [3] [4] [5] The cellular and anatomical distribution of σ receptors is not restricted to the central nervous system (CNS a ), [6] [7] [8] but extends to peripheral tissues such as blood vessels, adrenal glands, testicles, ovaries, and immune system. 9 There is increasing evidence that σ receptors have a neuromodulatory role in the CNS and are involved in the etiology of various psychiatric diseases 10 such as anxiety, schizophrenia, and depression. The correlation between the extent of toxic effects on CNS of some antipsychotic compounds and their σ receptor affinity is also documented. Furthermore, σ receptors may also have a potential role in neuromotor diseases such as dystonia and dyskinesia; 11 indeed, σ receptors are highly expressed in brain areas associated with the control of movement of facial muscles. 11 The σ 1 receptor subtype has been purified and cloned from several animal species and man. 12, 13 Its primary sequence is now available and shows remarkable homology with sterol C8-C7 isomerase from fungi. The σ 1 receptors exert a modulatory role on neurotransmitter systems such as dopaminergic, serotoninergic, and muscarinic systems 5, 14, 15 and on the NMDA-stimulated neurotransmitters' release. 16 Moreover, σ 1 receptors are involved in neuroprotective and antiamnesic activities, 17 modulation of opioid analgesia, 18 and attenuation of cocaine-induced locomotor activity and toxicity. 19 In addition, σ 1 antagonists have been shown to be effective against negative symptoms of schizophrenia without producing extrapyramidal side effects typical of traditional neuroleptics. 20, 21 On the other hand, the molecular identity of the σ 2 receptor subtype has not been fully determined, 12, 13 although a number of studies have presented evidence linking σ 2 receptors to potassium channels and intracellular calcium release in NCB-20 cells. 22, 23 Unlike the σ 1 subtype, σ 2 receptors may contribute to the acute side effects of typical neuroleptic drugs, and σ 2 antagonists are known to attenuate extrapyramidal effects, dystonic reactions, and tardive dyskinesia, 2, 14, 22, 24, 25 suggesting their potential use in the treatment of psychoses. 20, 21 Furthermore, σ 2 receptors are involved in the regulation of cell proliferation and maintenance of cell viability. They are highly expressed in several tumoral cell lines, 26, 27 where σ 2 agonists produce morphological changes and apoptosis. The σ 2 receptor agonists promote Ca 2þ release from endoplasmatic reticulum and mitochondrial stores, 28 with subsequent cell death by caspase-independent apoptosis. 27 Apoptosis may also be induced in tumoral cells by regulation of the sphingolipid pathway. 29 Therefore, σ 2 agonists may be useful as novel anticancer agents and as imaging agents in cancer diagnosis by positron emission tomography (PET) 30 and single photon emission computed tomography (SPECT). 31, 32 To date, well-known compounds characterized by a certain degree of selectivity for the σ 1 receptor subtype include (þ)-benzomorphans such as (þ)-pentazocine (PTZ) and (þ)-Nallylnormetazocine (NANM, SKF-10047), while haloperidol and 1,3-di-(2-tolyl)guanidine show high affinity for both receptor subtypes. 22 In our previous work 33 we described the synthesis and the affinities for the σ receptors of a series of substituted benzooxazolone derivatives 1a-j (Figure 1 ), in which the benzyl group was variously substituted at the phenyl ring. The benzooxazolone derivatives 1a-j have been designed according to the σ 1 receptor model proposed by Glennon, [34] [35] [36] under the following assumptions: (i) the benzooxazolone moiety may interact with a primary hydrophobic site corresponding to Glennon's phenyl "B" region; [34] [35] [36] (ii) the 4-methylpiperidin-1-yl spacer links the basic nitrogen atom to the benzooxazolone moiety; (iii) the substituted N-benzyl moiety may bind the secondary hydrophobic phenyl "A" region of the σ 1 receptorial model, modulating the binding affinity of the compounds for the σ receptors.
The relevant results indicated that the substituents on the phenyl ring can modulate the σ 1 and σ 2 binding affinities of these compounds. Indeed, all molecules show, to various degrees, a preference for σ 1 receptor sites, with the unsubstituted derivative and the corresponding para-substituted derivatives exhibiting the highest affinity. Particularly, the best result was reached with the 4-chloro substituted compound, with a K i (σ 1 ) value of 0.1 nM and a K i (σ 2 )/K i (σ 1 ) selectivity ratio of 4270.
In this work we synthesized (Scheme 1) a series of 3-[(Nbenzyl-N-ethylamine)alkyl]benzo[d ]oxazol-2(3H )-one derivatives 2a-k and 3a-k (Table 1) , with various substitutions at the benzene ring, to generate an adequate number of compounds for the purpose of developing a three-dimensional (3D) pharmacophore model for σ 1 receptor ligands.
Since the benzooxazolone moiety is considered to form a good interaction with a putative hydrophobic region in these receptors, this group has been maintained in the new molecular series. Moreover, the electronegative atoms of the oxazolone moiety may further contribute to the binding affinity. Effectively, electronegative atoms such as O or S are frequently present in very potent σ 1 ligands, bridging the aromatic component and the classical alkyl or cycloalkyl intermediate spacer linked to the basic nitrogen atom. 13, 36 On the basis of a molecular modeling study of σ 1 receptor ligands, Gund et al. 37 also concluded that there could be a secondary binding region that may surround the oxygen or sulfur atom of the molecules. In the other half of the molecule, the piperidin-4-ylmethyl core has been replaced by an alkyl spacer, endowed with greater conformal freedom. The choice of a propyl or butyl chain is dictated by the fact that both fall within the range of optimal distances between the basic nitrogen atom and hydrophobic primary site in the receptor model of Glennon. [34] [35] [36] All compounds obtained were subsequently tested in order to assess their affinity and their selectivity toward σ receptors.
As mentioned previously, the crystal structure of both σ 1 and σ 2 receptors remains unsolved to date. In the absence of a reliable 3D model of the target structure, ligand-based molecular modeling tools can be successfully employed to devise structural requirements crucial for receptor binding. The 3D quantitative structure-activity relationship (3D-QSAR) pharmacophore modeling is such an approach and constitutes a consolidated technique in drug design and discovery. The major goal this paper is the generation of a predictive pharmacophore model for σ 1 ligands. To develop the model, we resorted to the HypoGen method implemented in the Catalyst software package. 38 Starting with a training set of 31 σ 1 ligands, a pharmacophore model (also called a hypothesis) able to quantitatively correlate the estimated affinities with the corresponding measured values was generated. The model was then validated by statistical means and by its ability to predict the affinity of a further ensemble of different compounds (test set). Overall, we verified that our 3D-QSAR pharmacophore model was predictive not only within the training set but also for the test set compounds, with acceptable errors.
Chemistry
The substituted 3- The substituted 1-benzyl-N-phenylpiperidine-4-carboxamide derivatives 6a-c and the corresponding N-benzyl derivatives 7a-c were prepared starting from the commercially available 4-piperidinecarboxylic acid which was transformed into the corresponding N-boc-4-piperidinecarboxylic chloride by treatment with SOCl 2 under N 2 ( Table 2 and Scheme 2). A solution of aniline and triethylamine in CH 2 Cl 2 was added directly to the reaction mixture with a catalytic amount of DMAP. The reaction was carried out at room temperature under N 2 flux to afford N-phenyl-1-(tert-butoxycarbonyl)-piperidine-4-carboxamide 8, which was deprotected with TFA to yield the N-phenylpiperidine-4-carboxamide 10.
Following the same route described above and using benzylamine, N-benzyl-1-(tert-butoxycarbonyl)piperidine-4-carboxamide 9 was prepared, from which N-benzylpiperidine-4-carboxamide 11 was obtained after deprotection with TFA. From the piperidine-4-carboxamides 10 and 11, the corresponding 1-benzyl derivatives 6a-c and 7a-c were obtained by alkylation with the opportune benzyl chlorides.
Results and Discussion
On the basis of the interesting K i (σ 1 ) values of a series of benzo [d ] oxazolone derivatives 1a-j (Figure 1 ) we described in previous work, 33 we synthesized a series of new benzooxazolone derivatives 2a-k and 3a-k (Table 1) in which the 4-methylpiperidin-1-yl spacer linking the benzooxazolone moiety to the benzyl group was replaced by the 3-(N-methylamino)propyl and 4-(N-methylamino)butyl groups, respectively. The aim was to verify if these modifications might produce compounds retaining affinity for σ receptor sites. All compounds were tested to evaluate their K i values against both σ 1 and σ 2 subtypes (Table 3) . From the results obtained so far (Table 3 ), it appears that the substituents on the phenyl ring strongly modulate the σ 1 and σ 2 binding affinity of these compounds, butylene derivatives 3a-k having higher affinity than the corresponding propylene derivatives 2a-k, as in the case of compounds 1a-j. 33 The butylene intermediate chain determines the optimal distance between the primary B and secondary A hydrophobic centers proposed by the Glennon's model. [34] [35] [36] The compound with the highest affinity is the butylene derivative 3a (R = H), with K i (σ 1 ) value of 2.6 nM and an interesting selectivity ratio K i (σ 2 )/K i (σ 1 ) = 46.2. The para-substituted compound 3d (R=4-Cl), instead, still maintains an appreciable σ 1 affinity but has a selectivity ratio (K i (σ 2 )/K i (σ 1 )=5.1) lower than those of the unsubstituted derivatives.
Unlike the derivatives previously described, compound 3g (R=4-OCH 3 ) has no selectivity, showing a moderate affinity toward both receptors. On the other hand, compounds 3b and 3i-k show preference toward the σ 2 receptor. Specifically, compound 3k (R = 2,4-(CH 3 ) 2 ) has the highest σ 2 affinity (K i (σ 2 )=6.94 nM) and selectivity ratio (K i (σ 2 )/K i (σ 1 )=0.03) of the series.
For the development of a 3D quantitative structureactivity relationship (3D-QSAR) pharmacophore model, a training set was derived with 31 compounds from our series, considering structural diversity and the widest possible coverage of the in vitro affinity range (see Table 4 ). To validate the developed pharmacophore model, we then predicted the σ 1 affinity of the test set of piperidine-4-carboxamide derivatives 6a-c and 7a-c and the reference σ 1 ligands haloperidol 12, trifluperidol 13, and ifenprodil 14. Compounds 6a-c and 7a-c were synthesized (Scheme 2), their K i (σ 1 ) values were determined, and their estimated σ 1 affinities were compared with the experimental data ( Table 5) .
3D Pharmacophore Modeling. In this work we developed a three-dimensional pharmacophore model in order to have a tool to design a second generation of σ 1 receptor ligands. It is a widely accepted that 3D pharmacophore modeling is a well-behaved approach to quantitatively explore the common chemical characteristics among a considerable number of different structures. However, a computed pharmacophore model can only be as good as the information that it contains. To achieve a quality model, at least three must-obey rules should be respected in three-dimensional quantitative structure-activity relationship (3D-QSAR) generation: (i) the training set must include a wide population (at least 16 items) of diverse compounds covering at least 4 orders of magnitude of activity; (ii) the most active compound should be included in the training set; (iii) all biological data must be obtained by homogeneous procedures. 39, 40 In our case, a training set consisting of 31 compounds from our series was prepared by considering structural diversity and the widest possible coverage of the in vitro affinity range (see Table 4 ). The molecules in our training set were selected according to the following criteria: (i) the training set should contain structures from each series of active compounds; (ii) the training set should cover the molecular bioactivities (K i ) as widely as possible. Should there be only one compound with maximum or minimum order of bioactivity in a series, then this compound was assigned to the training set.
The HypoGen algorithm allows a maximum of five features to be considered in the pharmacophore generation process. Accordingly, from the 11 features available in the Catalyst features dictionary (see Experimental Section for details), we excluded all those that clearly did not match the chemistry of the molecules of the training set, such as positive charge (PC) and negative charge (NC), as all ligands were considered in their neutral form. Also, preliminary runs including the hydrogen bond donor (HBD) and hydrogen bond acceptor lipid (HBAl) features confirmed that these features were never used in the generation of the pharmacophore models, even though they were present and properly mapped on several molecules of the training set. Thus, the HBD and HBAl features were removed from the list. Moreover, as most of the molecules in the training set possess both hydrophobic aromatic and hydrophobic aliphatic groups, the specific hydrophobic aromatic (HYAr) and hydrophobic aliphatic (HYAl) features were both selected. The more generic hydrophobic feature (HY) was also chosen to optimize the substituents mapping on the phenyl ring. In summary, the following five chemical features were taken into account for hypothesis generation with HypoGen: hydrogen bond acceptor (HBA), hydrophobic aromatic (HYAr), hydrophobic aliphatic (HYAl), ring aromatic (Ar), and positive ionizable (PI).
In total, 10 hypotheses were generated by the HypoGen algorithm, all characterized by 5 features. The total hypothesis cost of these 10 best models varies between 124.1 for the best ranked model (Hypo1) to 151.2 for the lowest ranked one (Hypo10). Such a confined difference (27 bits) reflects both the homogeneity of the generated hypotheses and the adequacy of the molecular training set. The difference between the null and the fixed costs, which should be higher than 70 to guarantee a robust correlation, is 91 in our case. This corresponds to a chance of true correlation in the data greater than 90%. 41 Furthermore, in all the generated hypotheses the total costs are much closer to the fixed cost (103.1) than to the null cost (194.1), indicating that meaningful models are obtained. Finally, the root-mean-square deviations (rmsd) and the correlation coefficients (F) between estimated and experimental affinities range from 1.126 to 1.844 and from 0.896 to 0.566, respectively. As all the generated pharmacophores map the molecules of the training set in a similar way, the first model (Hypo1), characterized by the highest cost difference, the lowest rmsd, and the best F values, was selected for further analysis.
Hypo1 contains one hydrogen bond acceptor, two hydrophobic aromatic features, one hydrophobic feature, and one positive ionizable group. The affinities of the 31 compounds estimated using Hypo1 are reported in Table 4 , along with the experimental values and the relevant errors (expressed as the ratio of estimated to experimental values). This table clearly shows that 24 out of 31 molecules in the training set have errors less than 4 while the remaining 7 have errors less than 10. Figure 2A -C illustrates the selected Hypo1 pharmacophore model, while parts D, E, and F of Figure 2 show the mapping of compounds 1c, 1d, and 2h onto Hypo1, respectively.
In compound 1c, as seen in Figure 2D , the aromatic ring of the benzooxazolone moiety matches one of the HYAr features; the other HYAr feature is nicely overlapped by the additional phenyl ring. The carbonyl group and the basic nitrogen atom of the pyperidine ring match the HBA and PI functions, while the chlorine atom on the monosubstituted phenyl ring maps the remaining HY feature. Quite an analogous mapping is observed for 1d ( Figure 2E ). The estimated affinities for 1c and 1d are 0.27 and 280 nM, while the corresponding experimental affinities are 0.098 and 258 nM, respectively. Figure 2F is an example of a pharmacophore mapping of a compound that is less active than the former two. Compound 2h does not map all the features encoded in Hypo1. In fact, 2h maps the two HYAr functions, again by means of the two phenyl rings; the PI feature is still overlapped by the nitrogen atom of the cyclic/linear bridging moiety, and the HBA function is located over the carbonyl oxygen. However, it does not map the HY function. According to this partial mapping, this compound is predicted to be less active.
A critical step in automated pharmacophore generation is model validation, especially in those cases where the model has been generated for the purpose of predicting the activity of external sets of compounds or, as in our case, of estimating the activity of newly conceived molecular entities prior to their synthesis. The first method we used to check the robustness of our correlation was the prediction of the affinity of a further set of molecules, also called the test set, composed of six additional molecules from our series and three compounds taken from the literature 42 (see Table 5 ). The aim of this validation was to verify if our 3D pharmacophore model was able to predict the experimentally determined affinity values of the test set compounds. Interestingly, a good correlation coefficient (0.882) was observed when a regression analysis was performed by mapping the test set onto the features of the best pharmacophore hypothesis Hypo1. The predicted and the experimental K i values for the test set along with the respective errors are shown in Table 5 . The average error in predicting the affinity of the test set molecules is 2.5. Given the inherent simplicity of the pharmacophoric approach and considering the intrinsic variability of the biological responses, we can conclude that the ability of the present 3D pharmacophore model to predict the affinity of this series of σ 1 receptor ligands is quite satisfactory. Figure 3 shows the mapping of two test set molecules (7b and 12, respectively) to the σ 1 receptor pharmacophore model. For both compounds, the two phenyl groups match the HYAr functions, the chlorine atom fits the HY feature, the carbonyl oxygen atom provides the HBA function, and the basic nitrogen is located over the PI feature. Notwithstanding these good results, a second test was performed to check the statistical significance of the 3D pharmacophore model Hypo1, based on a randomization procedure. This was derived from the Fisher method using the CatScramble program available in the Catalyst suite of programs. According to the validation procedure, the experimental affinities of the compounds in the training set were scrambled randomly and the resulting new training sets were used for a number of new HypoGen runs. The parameters used in running these calculations were the same employed in the initial HypoGen calculation, and since a 98% confidence level was selected, 49 random hypothesis runs were performed. The results clearly indicate that randomization produced hypotheses with no predictive values similar or close to the corresponding Hypo1. Indeed, none of the outcome hypotheses had a lower cost score, better correlation, or smaller root-mean-square deviation than the initial hypothesis. Table 6 lists the first 10 lowest total score values of the resulting 49 hypotheses for our test set molecules. In conclusion, there is a 98% chance for the best hypothesis to represent a true correlation in the training set affinity data for the present classes of compounds.
Finally, a further statistical test, the leave-one-out method, which consists of recomputing the hypothesis by excluding from the training set one molecule at a time, was carried out. Basically, this test is performed to verify whether or not the correlation is strongly dependent on one particular compound in the training set. The test is positive if the affinity of each excluded molecule is correctly predicted by the corresponding one-missing hypothesis. The value of F, the feature composition of the pharmacophore, and the quality of the predicted affinity of the excluded molecule were used as measures for the assessment of the statistical test. For each of the 31 new hypotheses generated according to this method, we did not obtain meaningful differences between Hypo1 and each hypothesis resulting from the exclusion of one compound at a time.
Overall, the 3D pharmacophore model derived in the present work is quite simple, and it is in perfect agreement with another pharmacophore model for σ 1 receptors previously reported by Glennon et al., 34 in which a basic nitrogen is placed between two hydrophobic sites. Importantly, the primary hydrophobic site of Glennon's model is located at an optimum distance of 7-9 Å from the basic nitrogen. This corresponds well to our aromatic and aliphatic hydrophobic feature spheres (8.5 and 7.0 Å from the PI feature, respectively; see Figure 2C ). The second hydrophobic site, reported at a distance of 2.5-3.9 Å from the basic nitrogen in Glennon's model, is matched by the remaining HYAr, which is located at 3.6 Å from the PI feature in our 3D pharmacophore. Also, our model compares well, both in terms of feature type and geometrical characteristics, with a more general pharmacophore model recently obtained by Laggner et al. for σ 1 and the ERG2 protein. 42 As a concluding comment, we emphasize that only five-feature pharmacophore hypotheses were generated by Catalyst according to our procedure. This is significant for a number of reasons, first, because most prior published pharmacophores for σ 1 receptors contain only four features (as reviewed above), second, because our five-feature hypothesis does indeed represent a more stringent and significant model, and last, because it illustrates that Catalyst identified sufficient evidence in this structural data set to add or distinguish an additional feature or nuance not seen previously.
Conclusions
In this work we discussed how, from three series of newly synthesized compounds characterized by a broad range of affinity toward σ 1 receptors, we derived a three-dimensional pharmacophore model with quantitative predictive ability for these classes of molecules. The best generated pharmacophore model (Hypo1) consists of five features: two hydrophobic aromatic, one hydrophobic aliphatic, one hydrogen bond acceptor, and one positive ionizable group. Hypo1 reasonably predicts the affinity of the test set molecules with a correlation coefficient of 0.896 and shows the best statistical significance among all the generated models. Two validation tests, the Fisher test and the leave-one-out test, confirmed the statistical validity of our simple but effective 3D pharmacophore, excluding any possibility of a chance correlation between experimental and predicted affinity values. Finally, the model was predictive not only for the training set compounds but also for a test set of nine additional molecules, three of which were taken from the literature and not structurally related to our series.
Compared with other drug discovery tools, the pharmacophore approach has the significant advantage that it is fast and able to predict the activity of quite a large number of molecules in a relatively short time. Given the reasonable predictive ability of our model, we expect to exploit it in the development and optimization of our promising series of compounds. In particular, we will use this 3D pharmacophore to estimate the potential affinity of virtual libraries of newly designed, second generation σ 1 receptor ligands prior to synthesis and biological testing.
Experimental Section
Unless otherwise noted, starting materials and reagents were obtained from commercial suppliers and were used without purification. Melting points were determined with a Buchi 510 capillary apparatus and are uncorrected. Infrared spectra in Nujol mulls were recorded on a Jasko FT 200 spectrophotometer. Proton nuclear magnetic resonance ( 1 H NMR) spectra were determined on a Varian Gemini 200 spectrometer, and the chemical shifts are reported as δ (ppm) in CDCl 3 solution. Coupling constants J are expressed in hertz (Hz). Reaction courses and product mixtures were routinely monitored by thin-layer chromatography (TLC) on silica gel precoated F 254 Merck plates. ESI-MS spectra were obtained on a PE-API I spectrometer by infusion of a solution of the sample in MeOH. Elemental analyses (C, H, N) were performed on a Carlo Erba 1106 analyzer and were within (0.3 of the theoretical value.
Synthesis of Benzooxazolone Derivatives. 3-(3-Chloropropyl)-benzo[d ]oxazol-2(3H)-one (5a). 43 A mixture of benzo[d ]oxazol-2(3H)-one 4 (3.0 g, 22.22 mmol) and K 2 CO 3 (7.7 g, 55.55 mmol) was dissolved in 50 mL of CH 3 CN and the solution was refluxed for 10 min. 1-Bromo-3-chloropropane (8.7 g, 55.55 mmol) and a catalytic amount of KI were added, and the mixture was stirred for an additional 3 h at reflux temperature. The inorganic salts were filtered off, and the solvent was evaporated under reduced pressure. Distilled water (50 mL) was added, and the residue was extracted 3 times with CHCl 3 (3 Â 100 mL). The organic phase was separated and dried over anhydrous Na 2 SO 4 . The filtered solution was concentrated under reduced pressure, and the remaining oil was crystallized from n-hexane to afford a light-yellow solid. Yield 4.01 g (85%); mp 62-64°C. IR (Nujol): 1791 cm , and a catalytic amount of KI was dissolved in 50 mL of ACN, and the solution was refluxed and monitored by TLC. The inorganic salts were filtered off, and the solvent was evaporated under reduce pressure. Distilled water (50 mL) was added, and the residue was extracted 3 times with CHCl 3 (3 Â 100 mL). The organic phase was separated and dried over anhydrous Na 2 SO 4 . The filtered solution was concentrated under reduced pressure and the remaining oil was treated with an equimolar amount of oxalic acid in absolute ethanol to afford the oxalate salt, which was filtered and washed with cold ethanol. Yield 0.12 g (0.09 g of free base, 30%); mp 145-150°C. IR (Nujol): 1772, 2668 cm Synthesis of Carboxamide Derivatives. N-Phenyl-1-(tert-butoxycarbonyl)piperidine-4-carboxamide (8). 45 To a mixture of N-Boc-4-piperidinecarboxylic acid (2.12 g, 9.22 mmol), pyridine (1.90 mL, 23,6 mmol) and CH 2 Cl 2 (15 mL) and SOCl 2 (0.80 mL, 11.0 mmol) were added, under N 2 at room temperature, while stirring. After 25 min, a solution of aniline (0.95 g, 10.2 mmol), Et 3 N (4.50 mL, 32.3 mmol), and a catalytic amount of DMAP in CH 2 Cl 2 (15 mL) was added dropwise. The reaction was monitored by TLC. After 14 h, the organic phase was washed with 1 N HCl (2 Â 20 mL) and distilled water (2 Â 20 mL), dried with Na 2 SO 4 , and concentrated in vacuum to give 1.70 23 and were slightly modified as previously described. 33 Briefly, for the σ 1 receptor assay 250 μg of rat liver homogenate was incubated for 120 min at 37°C with 1 nM [ 3 H]-(þ)-pentazocine (PerkinElmer, specific activity 34.9 Ci/mmol) in 50 mM Tris-HCl, pH 8.0, 0.5 mL final volume. Nonspecific binding was defined in the presence of 10 μM haloperidol. The reaction was stopped by vacuum filtration through GF/B glass-fiber filters presoacked with 0.5% polyethylenimine, followed by rapid washing with 2 mL of ice-cold buffer. The filters were placed in 3 mL of scintillation cocktail, and the radioactivity was determined by liquid scintillation counting.
For the σ 2 receptor assay, 150 μg of rat liver homogenate was incubated for 120 min at room temperature with 3 nM [ Competition studies were done using at least 11 different concentrations of the ligand under investigation. As an internal control, three increasing concentrations of unlabeled (þ)-pentazocine (σ 1 receptors) or DTG (σ 2 receptors) were always included. The compounds were prepared as 10 mM stock solutions in 100% DMSO and diluted with Tris-HCl buffer on the day of the experiment. The final DMSO concentration in the incubation tubes was maintained at 0.1%.
The competition data for two to four separate determinations performed in duplicate were averaged by fitting to a fourparameter curve by means of the SigmaPlot software. Calculated IC 50 values and Hill's coefficients (n H ) are reported as mean values ( SEM. The corresponding K i values were obtained by the Cheng-Prusoff equation, as previously reported. 49 Molecular Modeling. Training and Test Sets. The model structures of all compounds were built using the Catalyst 2D-3D sketcher. 38 High quality conformational models are crucial for the development of predictive pharmacophore models. Accordingly, in this study we employed an ad hoc procedure to derive molecular conformations, instead of using those generated by Catalyst, for better quality in covering the lowenergy conformational space. Each molecular structure was subjected to energy minimization using the generalized CHARMM force field 50 until the gradient dropped below 0.05. The minimized structures were used as the starting point for subsequent conformational searches. A 10000-step Monte Carlo torsional sampling conformational search was conducted for each compound. Unique low-energy conformations within 20 kcal/mol of the corresponding global energy minimum were collected for each molecule. A conformation was considered unique only when the maximum displacement of at least one heavy atom was greater than 0.5 Å . A maximum of 250 unique conformations were recovered for each compound. The classical conformational search was also carried out using the Poling algorithm [51] [52] [53] and the CHARMM force field 51 as implemented in the Catalyst program for comparison. The "best quality" generation option was adopted to select representative conformers over a 0-20 kcal/mol interval above the computed global energy minimum in the conformational space, and again, the number of conformers generated for each compound was limited to a maximum of 250. Comparing the results of the two conformational searches, we verified the existence of considerable differences between the two approaches in generating conformations for saturated six-member rings such as piperidine. This group is quite common in drug molecules and constitutes a popular molecular scaffold. A survey of the crystal structures of druglike molecules and protein/ligand complexes available in the literature and in public databases reveals that this saturated ring overwhelmingly adopts lowenergy chair conformations. The conformational search conducted with the typical Catalyst settings described above, however, generated predominantly twisted conformations that might lead to an incorrect mapping of this functionally important group. In comparison, the alternative procedure of conformational search produced a considerable number of chair conformations for this heterocyclic moiety. The main drawback of this technique, however, is that it takes considerable longer to generate the relevant conformational models. Nonetheless, as the spirit of the work was the generation of a predictive 3D pharmacophore model for these classes of compounds, we considered it worthwhile to use more accurate conformational models.
On the basis of the conformations for each compound, the HypoGen module of the Catalyst 4.9 software package was used to generate three-dimensional pharmacophore models. During hypotheses generation, the software attempts to minimize a cost function containing two main terms: the first penalizes the deviation between the estimated affinities of the training set molecules and their experimental values, while the second penalizes the complexity of the hypothesis. The uncertainty factor for each compound represents the ratio range of uncertainty in the affinity value based on the expected statistical irregularity of biological data collection. Uncertainty influences the first step (also called the constructive phase) of the hypothesis generating process. In this work, an uncertainty of 1.1 was preferred over the default factor of 3.0, as the experimental affinities of our compounds barely span the required 4 orders of magnitude.
Briefly, a pharmacophore captures the three-dimensional arrangement of the structural features shared by all active molecules that are presumably essential for the desired pharmacological activity. These features include hydrogen bond donors (HBD) and acceptors (HBA), hydrophobic groups (HY), aromatic rings (RA), positively charged/ionizable groups (PC/PI), and negatively charged/ionizable (NC/NI) moieties. In addition, shape restraints and excluded volume effects can also be incorporated in the 3D-QSAR pharmacophores to account for the framework of the target active site. These popular modeling techniques find many practical applications in drug design. For instance, they can be used to align structurally unrelated lead compounds, thus identifying the groups in each molecular structure that play an important role for the corresponding biological activity. Moreover, the nonessential parts of the molecules can be altered to improve their physicochemical or pharmacokinetic properties, and new molecular scaffolds can be designed to establish novel patent space. Last but not least, pharmacophore models have been applied with success in virtual screening to extract molecular entities for biological activity testing from large, proprietary, or public databases. 54 An analysis of the functional groups characterizing our compounds suggested that hydrophobic aromatic (HYAr) and aliphatic (HYAl) features, hydrogen bond acceptors (HBA), positive ionizable (PI), and ring aromatic (RAr) features could effectively map the critical chemical features and hence describe the σ 1 receptor affinity of our compounds. Accordingly, these five features were selected to constitute the essential information in the automated hypothesis generation process.
Three validation procedures were used to determine the statistical relevance and the validity of the proposed 3D pharmacophore models: the test set prediction method, the CatScramble method, and the leave-one-out procedure. In this work, the first procedure consisted of a collection of further, different compounds into a test set and of performing a regression analysis by mapping the test set molecules onto the best pharmacophore hypothesis. The high correlation coefficients obtained using the test set compounds revealed the good correlation between the actual and estimated affinities and hence the predictive validity of the corresponding 3D hypothesis. The CatScramble validation procedure is based on Fisher's randomization test. 55 The goal of this type of validation is to check whether there is a strong correlation between the chemical structures and the biological activity. This is done by randomizing the affinity data associated with the training set compounds, generating pharmacophore hypotheses using the same features and parameters employed to develop the original pharmacophore model. The statistical significance is calculated according to the following formula:
where x is the total number of hypotheses having a total cost lower than the original (best) hypothesis and y is the total number of HypoGen runs (initial þ random runs). Thus, 49 random spreadsheets (i.e., 49 HypoGen runs) have to be generated to obtain a 98% confidence level. Should any randomized data set result in the generation of a 3D pharmacophore with similar or even better cost values, rootmean-square deviations, and correlation coefficients, then it is likely that the original hypothesis does reflect a chance correlation.
Finally, the leave-one-out test checks if the correlation between experimental and computed affinities is heavily dependent on one particular molecule of the training set by recomputing the pharmacophore model with the exclusion of one molecule at a time. Accordingly, 31 new training sets were derived, each composed of 30 molecules, and 31 HypoGen calculations were performed under the same conditions. For each run, the hypothesis characterized by the lowest total cost was employed to predict the affinity of the excluded compound and to estimate the new correlation coefficient.
All PDB structures and 3D hypotheses generated in this work are available from the authors upon request.
